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Faithful modeling of mixed-lineage leukemia in murine cells has been difficult to achieve. We show that ex-
pression of MLL-AF9 in human CD34+ cells induces acute myeloid, lymphoid, or mixed-lineage leukemia in
immunodeficient mice. Some leukemia stem cells (LSC) were multipotent and could be lineage directed by
altering either the growth factors or the recipient strain of mouse, highlighting the importance of microenvi-
ronmental cues. Other LSCwere strictly lineage committed, demonstrating the heterogeneity of the stem cell
compartment in MLL disease. Targeting the Rac signaling pathway by pharmacologic or genetic means
resulted in rapid and specific apoptosis of MLL-AF9 cells, suggesting that the Rac signaling pathway may
be a valid therapeutic target in MLL-rearranged AML.INTRODUCTION
As its name implies, the mixed-lineage leukemia (MLL) gene on
chromosome 11q23 is rearranged in both acute myeloid and
acute lymphoid leukemia (AML and ALL) (De Braekeleer et al.,
2005; Dimartino and Cleary, 1999). Reciprocal translocations
that fuse the amino terminus ofMLL to a diverse group of partner
genes are found in 7% of AML and 10% of ALL. In AML, the most
common partner gene for MLL is AF9 on chromosome 9p22.
MLL-AF9-expressing AML cells have morphologic and immuno-
phenotypic features consistent with myelomonocytic differentia-
tion. Patients with an MLL-AF9 fusion have an intermediate to
poor prognosis, suggesting that MLL-AF9 expression is associ-
ated with a more aggressive disease that includes resistance to
chemotherapy (Schoch et al., 2003).The propensity for MLL fusion proteins to transform primary
hematopoietic progenitor cells (HPC) as independent, dominant
oncogenes has been recapitulated in various mouse model
systems. Knockin of MLL-AF9 induces AML with a latency of
5 months (Corral et al., 1996). Retroviral gene transfer of MLL
fusion genes into murine HPC has demonstrated that both
MLL and fusion partner sequences are necessary and sufficient
for transformation and that either HSC or more differentiated
HPC can be transformed and function as leukemia stem cells
(LSC) (Corral et al., 1996; Cozzio et al., 2003; DiMartino et al.,
2002; Krivtsov et al., 2006; Lavau et al., 1997; So et al.,
2003b; Somervaille and Cleary, 2006). Despite the elegance
of these studies, the extent to which murine HPCs mirror the
processes of the naturally occurring human disease is uncer-
tain. In particular, the B cell leukemia associated with MLLSIGNIFICANCE
Mousemodels of leukemia have elegantly defined the nature of the LSC implicated in AML-associated 11q23 leukemias but
have proven more limited in modeling the lymphoid and biphenotypic aspects of the disease. We show that transduction of
human CD34+ cells and transplantation into immunodeficient mice enables efficient modeling of mixed-lineage leukemia
associated with MLL-AF9 expression. Our data demonstrate that some MLL-AF9-expressing LSC are multipotent, while
others are lineage restricted, demonstrating the heterogeneity of the LSC in mixed-lineage leukemias. The role of microen-
vironment appears dominant over an instructive signal contributed by the fusion partner. This human-based system should
prove useful in addressing the lineage promiscuity of MLL leukemias and allow testing of different therapeutic strategies.Cancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc. 483
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MLL-AF9 Transforms Primary Human CD34+ Cellsfusion protein expression is not readily modeled in the mouse
(Lavau et al., 1997).
In humans, MLL-ENL translocations are found equally repre-
sented in AML and ALL disease, yet the mouse model is highly
biased toward myeloid leukemias (Lavau et al., 1997). It has re-
cently been shown that MLL-ENL induces acute B-lymphocytic
leukemia (B-ALL) when expressed in human HPC, with no devel-
opment of AML (Barabe et al., 2007). Whether this disparity is
due primarily to species-specific differences intrinsic to the he-
matopoietic cell or is an effect of microenvironment differences
(the xenograft model versus the pure murine system) is an
open question. This study went on to show that the MLL-AF9
oncogene, which is almost exclusively associated with AML in
humans, induced AML in only 18% of recipient mice (2/11
mice) and B-ALL or MLL in 82% (9/11 mice). These data are
used to argue for an instructive role of the fusion partner in
MLL translocations, although neither MLL-ENL nor MLL-AF9 is
primarily instructive for the B cell lineage in human clinical dis-
ease. The small sample size in this study does not permit defin-
itive conclusions to be drawn; it is equally possible that factors
other than the translocation fusion partner may be playing
dominant roles in lineage decision, including microenvironment
effects.
Here we report that retroviral-mediated transfer of an MLL-
AF9 fusion cDNA into normal human CD34+ cord blood (CB)
cells leads to the establishment of cultures that produce a fatal
leukemia in NOD/SCID mice. These cells proliferate indefinitely
in vitro and in vivo, providing ample material for experimental
manipulation and characterization. Gene expression profiling
of MLL-AF9-expressing myeloid cultures reveals a signature
that closely parallels that of patient AML samples containing
the MLL-AF9 fusion. In addition, the mixed-lineage nature of
the leukemia is readily modeled in this system upon manipulation
of environmental cues, implying that the lineage promiscuity of
samples expressing the MLL-AF9 fusion protein may be primar-
ily affected by the microenvironment in which the leukemia stem
cell resides. This system provides a useful tool for the identifica-
tion and validation of much-needed therapeutic targets for MLL-
rearranged leukemia. In particular, we identify the Rac signaling
pathway as a critical regulator inMLL fusion leukemias and dem-
onstrate that treatment of these cells with a Rac inhibitor or ge-
netic ablation of Rac signaling induces cell-cycle arrest and
apoptosis.
RESULTS
MLL-AF9 Expression Immortalizes Human
CD34+ CB Cells
To determine whether MLL-AF9 would transform human CD34+
CB cells, we transduced cells with retroviral vectors expressing
MLL-AF9 (MA9) as a bicistronic mRNA with the enhanced green
fluorescent protein (EGFP) and independently with a second
MA9 construct that did not coexpress EGFP (Figure S1). Results
using the two different constructs were similar, and most exper-
iments were subsequently performed using the MA9-PuroR con-
struct. Transduction efficiencies were 5%–60% for MA9 vectors
and 20%–80% for control vectors (Figure 1A and data not
shown). There was no significant skewing of the cell population
2 days after transduction as shown by surface expression of pro-484 Cancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc.genitor and myeloid-specific surface antigens, with the majority
of cells expressing CD34, CD117 (c-kit), and CD13 (Figure 1A).
MA9-transduced cells became immortal and doubled in number
every 2–3 days, while control cells stopped proliferating between
weeks 5 and 10 (Figure 1B). Expression of CD33, CD11b, CD13,
CD14, and CD15 indicated a myelomonocytic lineage, presum-
ably beyond the progenitor compartment given the lack of
CD34 expression (Table S1). Long-term cultured MA9 cells
(myeloid growth conditions) failed to differentiate toward the ery-
throid or B lymphoid lineages under conditions that support dif-
ferentiation by control CB cells (data not shown; Mulloy et al.,
2003; Wunderlich et al., 2006). MA9 cells remained cytokine
dependent for growth. In contrast to their murine counterparts,
however, the human MA9 cells demonstrated a particular de-
pendence on FLT3L that could not be readily overcome even
with the combined use of SCF, GM-CSF, and IL-3 (Figure 1C).
An essential component in malignant transformation is the ability
to maintain telomere length, a function attributed to the activity of
telomerase in most human cancers (Flores et al., 2006). MA9
cells reproducibly demonstrated telomerase activity at early
and late times in vitro (Figure 1D). To determine whether this
might be an immediate effect of MA9 expression on the hTERT
promoter, we analyzed cells for levels of telomerase mRNA ex-
pression shortly after transduction. CB cells transduced with
the GFP-expressing control and MA9 viruses were analyzed at
day 7, when the majority of cells were positive for GFP expres-
sion. Transcript levels of MA9 were readily detected in two sep-
arate MA9-transduced CB cultures, while hTERT expression
levels were unchanged (Figure 1E). To confirm these results in
a different system, we used the U2OS osteosarcoma cell line,
which is hTERT negative. Transduction followed by puromycin
selection demonstrated that, in this system as well, hTERT levels
were unchanged, while MA9 expression was easily detected by
Q-PCR as early as day 4 after transduction (Figure 1E).
MLL-AF9 is occasionally associated with B-ALL (Secker-
Walker, 1998). The clonal relatedness of the myeloid and B-lym-
phoid diseases is currently unclear, and presently there is no
reproducible system for generating a B cell leukemia using the
available mouse models for MLL-AF9. We transduced human
CD34+ cells and cultured the cells under conditions that pro-
mote B cell outgrowth (Mulloy et al., 2003). MA9 cells became
immortal and displayed a mixed-lineage phenotype, with
CD19+CD10+/CD20 cells dominating the culture and variable
levels of CD33+CD19 cells also present (Figure 1F). Thus, MA9
transduction of CD34+ cells results in immortalized myeloid and
B-lymphoid cells, and the culture conditions play a critical role in
determining the lineage outcome of the resulting culture.
MLL-AF9-Expressing Cells Produce Acute
Leukemia in NOD/SCID Mice
MA9 cells were injected into nonobese diabetic/severe com-
bined immunodeficient (NOD/SCID [NS]), NS-b2M
/ (NS-
B2M), and NS mice that are transgenic for the human cytokine
genes SCF, GM-CSF, and IL-3 (NS-SGM3) (Feuring-Buske
et al., 2003). In NS-SGM3 mice, cell lines as well as newly trans-
duced cells (direct inject) induced AML with a median latency of
5 weeks and 7 weeks, respectively (Figure 2A). Cells from the
myeloid and lymphoid cultures both resulted in AML in these
mice. The disease resembled aggressive myelomonocytic
Cancer Cell
MLL-AF9 Transforms Primary Human CD34+ CellsFigure 1. MLL-AF9 Expression Supports Long-Term Proliferation and Maturation Arrest of CD34+ Cord Blood Cells
(A) Immunophenotype of MLL-AF9-positive and -negative cells on day 2 after transduction.
(B) MLL-AF9 expression results in immortalization of primary CB cells. A growth curve charts the differences in proliferative capacity between control (MIG) and
MLL-AF9-positive (MA9) cells.
(C) MA9-expressing cells are particularly sensitive to FLT3L for proliferation. Cells cultured in the presence of FLT3L alone, SGM3, SGM3/F, and (+) (S/T/F/3/6),
respectively, were counted by trypan blue dye exclusion after 1 week. Results are expressed as mean ± standard deviation (SD).
(D) Telomerase activity was analyzed in MA9 cells grown for varying periods of time in vitro. Cord blood cells and the leukemia cell line Kasumi-1 were used as
controls. W, weeks.
(E) hTERT and MLL-AF9 transcript levels were analyzed by Q-PCR using Sybr Green and the standard curve method, with two different primer sets for hTERT. The
U2OS cells were analyzed 4 days after transduction and puromycin selection, and the cord blood samples were tested at day 7 when the majority of cells in
control and MA9 cultures were GFP+. Two independent cord blood samples were used and showed identical results. Results are shown as mean ± SD, with
asterisks indicating significance of p % 0.05. hTERT transcript levels were essentially negative in U2OS, with signals detected at amplification cycles similar
to no template control.
(F) Cytospins and flow cytometric analysis of long-term cultured cells grown under myeloid and lymphoid conditions. Scale bars represent 10 mm.leukemia with blast cells present in the peripheral blood, BM,
spleen, and liver (Figures 2A and 3). Flow cytometry confirmed
the myelomonocytic lineage of the leukemic cells (Figure 2A). In-
terestingly, most cells expressed the NK-associated surface
molecule NCAM-1 (CD56), which is aberrantly expressed onup to 40% of MLL-fusion AMLs (Baer et al., 1998). Occasionally
a leg tumor developed in those mice that were injected by the in-
trafemoral route, implying that the leukemic cells are able to form
granulocytic sarcomas (Figure 3C). The median latency of sec-
ondary disease was 5 weeks, not significantly different thanCancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc. 485
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MLL-AF9 Transforms Primary Human CD34+ Cellsthe latency of the primary AML (Figure 2A). However, when ana-
lyzed as paired samples, a significantly shorter latency was
apparent in the secondary animals (Table S2).
Cells injected into NS or NS-B2M mice resulted in a mix of
AML, B-ALL, and acute biphenotypic leukemia (ABL; defined
as a leukemia with 20% or more of cells coexpressing myeloid
and lymphoid markers). There was no significant difference in
latency between disease in NS or NS-B2M mice (Figure S2A).
Direct inject cells induced B-ALL or ABL (7/7 injections) in NS
or NS-B2M mice with a median latency of 14.5 weeks (Figure 2B).
This is similar to what has recently been published, with the ex-
ception that we did not observe any AML disease upon direct
inject into NS mice (Barabe et al., 2007). However, these same
cells uniformly induced AML in NS-SGM3, indicating the primacy
of microenvironment on leukemia development (Figure 2A). In
NS mice, the peripheral blood, spleen, liver, lung, kidney, and
lymph nodes were infiltrated, with blast cells displaying a pro/
pre-B phenotype (Figures 2B and 3). In addition to B-ALL or
ABL leukemia, there was often a separate population of cells
Figure 2. MLL-AF9-Expressing Cells Pro-
duce Leukemia in Immunodeficient Mice
MA9 myeloid or lymphoid cultures (cell line) and
freshly transduced CB cells (direct inject) were in-
jected into NS-SGM3 mice (A) and NS or NS-B2M
mice (B). Mice were sacrificed upon signs of ill-
ness. A Kaplan-Meier survival plot is shown for
each cohort of animals. Wright-Giemsa-stained
BM cytospins and peripheral blood smears indi-
cate that the circulatory system is full of immature
myeloid or lymphoid blast cells. Scale bars re-
present 10 mm. Cells from mouse bone marrow,
spleen, and liver were stained for human lineage
differentiation markers. Representative samples
from an AML and B-ALL/ABL mouse are shown.
that resembled AML disease, implying
that independent LSC were expanding
in these mice or that the LSC was able
to promote both AML and ALL in the
same mouse. Cell lines cultured under
myeloid conditions reproducibly induced
only AML, with a latency of approximately
10 weeks (7/7 mice). In contrast, lym-
phoid cultures induced both AML (2/21
mice) and B-ALL or ABL (19/21 mice)
(Figure 2B and Figure S2B). Median la-
tency using lymphoid cell lines was 13.5
weeks, similar to that observed upon di-
rect injection of freshly transduced CB
cells (14.5 weeks) (Figure 2B). Injection
of B-ALL samples into secondary recipi-
ents induced a significantly more rapid
disease, suggesting that the B-ALL cells
had acquired additional ‘‘hits’’ during the
primary in vivo phase (Figure 2B). When
separated into type of disease, AML oc-
curred significantly faster than B-ALL/
ABL in these mice but was still slower
than the AML that resulted upon injection into NS-SGM3 (Figures
S2C and S2D). This strongly implies that the human cytokines
supplied by the transgenes in NS-SGM3 are not only skewing
the disease to a myeloid phenotype but are also shortening the
latency of the leukemia. Results of all mouse experiments are
summarized in Table 1.
ChromosomeAneuploidy andOligoclonal ExpansionAre
Evident in the Cultured Cells as Well as in the Leukemia
Samples
Chromosome changes were observed in some of the cell cul-
tures as well as in some leukemia samples, but this was not uni-
formly seen (Table S3). Clonal evolution was evident in some
samples, but gross karyotypic abnormalities were not required
for disease induction (Table S3). All of the MA9 cell cultures dis-
played a polyclonal to oligoclonal pattern of retroviral integration
at early time points in vitro, which became less complex over
time (Figure 4A). Injection of week 3 MA9.6 cells into two mice
(NS-SGM3) resulted in the induction of AML in each mouse after486 Cancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc.
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MLL-AF9 Transforms Primary Human CD34+ Cellsapproximately 8 weeks, with clonal patterns present in each of
the AML samples that were distinct from the in vitro long-term
culture (9.6, 9.6#1, and 9.6#2 in Figure 4A). From a direct
injection experiment, five separate mice displayed unique
mono- and oligoclonal integration patterns in each of the result-
ing leukemias, again indicating that separate LSC populations
were inducing these diseases (Figure 4B). This data would indi-
cate that more than a single clone had acquired leukemogenic
potential upon MA9 expression, and that transformation is a
rapid event in human HPC upon expression of the MLL-AF9
fusion protein.
Figure 3. Hematoxylin and Eosin-Stained Paraffin Sections Demon-
strate Disruption of Organ Architecture Due to Tumor Infiltration
Organs and representative mice from animals with human AML disease (A) and
human B-ALL disease (B). Arrows indicate spleen and liver, and arrowheads
show the enlarged lymph nodes in the B-ALL mouse. The asterisk highlights
a leg tumor that is forming in the AML animal, which occasionally occurred af-
ter intrafemoral injection. A representative leg tumor is shown in (C). Scale bars
represent 100 mm unless indicated otherwise.
Table 1. Summary of Mouse Leukemia Experiments
Direct Inject Myeloid Lines Lymphoid Lines
N/S ND AML(3);11 ALL(8);15
N/S-B2M ALL(7);15 AML(4);10 AML(2);8/ALL(11);15
N/S-S/GM/3 AML(12);7 AML(18);4 AML(4);12
For simplicity the ABL disease is included as ALL. ND, not done. Disease
type, number of mice (in parentheses), and median latency in weeks are
indicated.The LSC in MLL-AF9 Mixed-Lineage Leukemias
Is Heterogeneous
To determine whether cell culture conditions could influence dis-
ease phenotype, we injected a week 4 myeloid culture and
a week 4 lymphoid culture (both resulting from the same CB
transduction) into NS-B2M mice (Figure 4C). These injections re-
sulted in AML from the myeloid cell culture (4/4 mice) and B-ALL
from the lymphoid cell culture (4/4 mice) after 11–18 weeks.
Southern blot analysis revealed that at least one B-ALL and
one AML were clonally related, even though the predominant
phenotype of each disease was clearly unique (Figures 4D–4F).
The clonal identity was confirmed using a different restriction en-
zyme (Figure 4E). Thus, the same LSC can be influenced by the
culture microenvironment to promote myeloid or lymphoid ex-
pansion and induce either AML or B-ALL/ABL, respectively.
The clonal relatedness of phenotypically unique leukemias
implies that a leukemia stem cell expressing MA9 can be multi-
potent. Whether this is always the case and whether a multipo-
tent cell is an obligate target for MLL fusion protein function in
human cells is currently unknown. We separated the myeloid
(CD19CD33+) and lymphoid (CD19+CD33) populations
from a mixed culture by cell sorting and found that the
CD19+CD33 cells were able to regenerate a CD19CD33+
cell type, while the CD19CD33+ cells were committed to the
myeloid lineage and could not regenerate CD19+ cells even un-
der lymphoid culture conditions (Figure 5A). Clonal analysis by
Southern blotting showed that the original CD33+ LSC was
a unique and independent leukemia population in this culture.
However, the CD19CD33+ population that was generated
from the CD19+ sorted cells showed a clonal integration pattern
identical to the CD19+ cells, demonstrating that this CD33+ pop-
ulation was in fact a progeny of the CD19+ LSC (Figure 5B). All
populations of cells were able to proliferate robustly and also
generated leukemia in vivo (data not shown). The morphology
of the cells indicated that the surface phenotype was an accurate
representation of the identity of the cells (Figure 5C). Interest-
ingly, in contrast to the myeloid-restricted CD19CD33+ LSC
from this population, some CD19CD33+ cells from other sam-
ples gave rise to both CD33+ AML and CD19+ ALL (Figure 5D).
These data suggest that MLL-AF9-expressing LSC can be line-
age restricted as well as multipotent, demonstrating the hetero-
geneity of the LSC in mixed-lineage leukemias.
Gene Expression Profile ofMLL-AF9-Expressing Cells
Resembles Human AML with 11q23 Translocations
Subsetsof human leukemiaexhibit characteristic and robust gene
expression signatures, defined on the basis of specific clonal
chromosomal rearrangements (Armstrong et al., 2002; Bullinger
et al., 2004; Lacayo et al., 2004; Ross et al., 2004; Valk et al.,
2004). To compare the gene expression profile of MA9 cells to pri-
mary AML samples, we assessed global gene expression for sev-
eral independently derived MA9 cultures using microarrays. As
comparison samples, we used cell lines expressing one of the
CBF fusion genes,AML1-ETO orCBFb-MYH11 (AE and CM), cul-
tured under the same conditions. Transduction of normal CB with
AE or CM also results in cultures with long-term proliferative po-
tential (Mulloy et al., 2003; Wunderlich et al., 2006). In total, nine
MA9 cultures and nine CBF cultures were analyzed using the Af-
fymetrix HGU133-Plus2.0 chip. The publicly available data fromCancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc. 487
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MLL-AF9 Transforms Primary Human CD34+ CellsFigure 4. Oligoclonal Outgrowth Is Detected In Vivo as Well as In Vitro
(A) Samples were collected from culture and from affected mice at the indicated times, and genomic DNA was digested with HinDIII or EcoR1 to detect clonal
integration of provirus using a GFP probe. Polyclonal to oligoclonal patterns are present at early time points in vitro, with oligoclonal to monoclonal integrations
detected after extended growth.
(B) MA9-transduced CB cells were injected immediately after transduction and leukemic cells from sick mice were analyzed for integration site by Southern
blotting. *Background band.
(C–F) Cells from MA9.16 myeloid and lymphoid cultures were injected into NS-B2M mice. Upon illness, leukemic cells were recovered and analyzed by Southern
blotting for clonal relatedness. Organs from the clonally related leukemias shown in (D) were analyzed for myeloid and lymphoid markers by flow cytometry.two large AML microarray studies were used for comparison
(Ross et al., 2004; Valk et al., 2004). Samples from the two public
data sets were combined and processed as described in the Ex-
perimental Procedures to generate a list of the top 100most differ-
entially expressed genes between CBF patient samples and MLL
patient samples (Table S4). Both patient and culture samples
were then analyzed using principal component analysis. Two ma-
jor groups were identified corresponding to the CBF and MLL pa-
tient samples (Figure 6A). All of the cell culture samples segre-
gated according to fusion gene status, with the cell lines tending
to cluster more closely with the samples from the pediatric AML
data set (Ross) than to the adult samples (Valk). This separation488 Cancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc.is also apparent in the two-dimensional dendrogram resulting
from the hierarchical clustering of the samples shown in
Figure 6B. For the MLL group, the cell culture samples behave
as a subset within the Ross data set, implying that these samples
are even more closely related to the pediatric patient samples
than are the adult AML samples. K-means clustering also demon-
strated that the MLL culture samples were highly related to the pri-
mary pediatric samples (Figure S3). We used a simple Support
Vector Machine (SVM; linear kernel function and least-squares
optimization) for classification of leukemia samples based on the
top 10 or the top 7 most differentially expressed genes in CBF
versus MLL patient samples and found that the classification
Cancer Cell
MLL-AF9 Transforms Primary Human CD34+ Cellsaccuracies were 100% for the cell culture samples. In addition,
class assignment accuracies of randomly chosen training and
test data sets from the pool of patient and cell culture samples
were assessed by 10-fold crossvalidation. An average classifica-
tion accuracy of 99.63% was observed when utilizing the same
parameters for the SVM. We analyzed three genes by qPCR
that have previously been identified as differentially expressed
in MLL leukemias (HOXA9, FLT3, and SPARC) (Bullinger et al.,
2004; DiMartino et al., 2006; Ross et al., 2004; Valk et al., 2004).
HOXA9 and FLT3 were highly expressed in four MA9 samples
compared to four AE samples, and SPARC was underexpressed
in the MA9 samples (Figure S4). There was no difference in the ex-
pression of these three genes in the MA9 samples that were re-
covered from mice with leukemia (n = 2) compared to the same
samples prior to injection (Figure S4). Thus, the transcriptome of
these experimentally created cell lines extensively parallels that
of primary leukemia cells from AML patients with MLL fusions.
Signaling through the Rac Pathway Is Critical
forMLL-AF9-Induced AML
The specific signaling pathways downstream of MLL fusion pro-
teins are only beginning to be understood. Recently, Somervaille
et al. showed that the activity of the small GTPase proteins Rac1
and CDC42 are specifically increased in murine cells expressing
MA9 (Somervaille and Cleary, 2006). We used the small-molecule
inhibitor of Rac, NSC23766, to determine the role of this signaling
pathway in MLL leukemogenesis (Cancelas et al., 2005; Gao
et al., 2004; Thomas et al., 2007). Total protein levels of Rac1
and CDC42 were not consistently different between MA9 cells,
control CB cells, and the preleukemia cell cultures expressing
Figure 5. CD19+ Cells Generate Myeloid
and Lymphoid Progeny
(A) A mixed culture was separated by cell sorting
into CD19+33 and CD19-33+ populations. Cells
were grown for 1 month in the indicated cytokines
and stained for the indicated surface molecules.
Only the 19+33 population of cells was able to
regenerate the lineage potential of the parent
population.
(B) Southern blot analysis was performed on the
indicated populations of cells. The original
CD33+ population is clonally unique and repre-
sents an AML LSC present in the parent popula-
tion. The CD33+ population generated from the
CD19+ sorted cells [(CD19+)/CD33+] shows
clonal identity to the B-ALL LSC present in the
parent culture.
(C) Cells from each population were analyzed by
Wright-Giemsa staining 1 month after sorting.
Scale bars represent 10 mm.
(D) Some CD33+ clones were able to produce
B-ALL, while others gave rise to pure AML in
NOD/SCID mice.
AML1-ETO (Figure S6A). We confirmed
the published findings that NSC23766
specifically affects the activation of Rac
and does not interfere with the activity of
the closely related small GTPase CDC42
(Figure S6B). Interestingly, a dose-depen-
dent effect of NSC23766 on cell proliferation was realized that
was specific for MA9 cells, with little to no effect on control CB
cells or the AE cultures (Figure 7A). Inhibition correlated with a de-
crease in cycling cells (S/G2/M phase) and a significant increase
in Annexin V+ cells, indicating that loss of Rac signaling in MA9
cells resulted in cell-cycle arrest and apoptosis (Figures 7B and
7C). It has previously been shown that Bcl-2 family members
are downstream of Rac signaling (Yang et al., 2000). We analyzed
cells 24 hr after drug treatment and found that the Bcl-xL protein
was targeted for degradation specifically in the MA9 cells, with no
effects detected in either CB or AE cells (Figure 7D). A slight effect
on bcl-2 protein was also detected at 24 hr in MA9 cells. To deter-
mine whether these effects were specifically mediated by Rac in-
hibition, we used lentiviral constructs coexpressing the yellow
fluorescent protein (YFP) to deliver shRNA targeting human
Rac1 to the MA9 cells. Apoptosis was detected specifically in
those MA9 cells expressing either of two independent shRNA tar-
geting Rac, but not in scramble-control transduced cells or in AE
cells targeted with the same lentiviral constructs (Figure 7E). The
increase in apoptosis in the MA9 cells expressing Rac shRNA was
statistically significant (Figure 7F). Protein levels of Rac1 were
significantly decreased in the cultures expressing Rac shRNA
(Figure 7G). Thus, the Rac signaling pathway is essential for the
growth and survival of MA9 cells, likely via induction of cell-cycle
progression and Bcl-xL/Bcl-2-mediated survival.
DISCUSSION
Mouse models have proven to be invaluable tools for the under-
standing of human cancer. Nevertheless, significant differencesCancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc. 489
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MLL-AF9 Transforms Primary Human CD34+ Cellsbetween the genetic makeup of mice and humans make it diffi-
cult to directly extrapolate observations made in the former to
a clinical disease in the latter. Unlike outbred human populations,
mouse strains are genetically homogeneous and homozygous
across all or most loci. The relative importance of a particular
mutation or gene expression pattern to oncogenesis may be
over- or underestimated in this context. Normal primary human
cells offer a potentially more relevant target for the study of on-
cogene function. However, these cells have historically proven
to be resistant to neoplastic transformation by a single oncogene
(Hahn et al., 1999). We show here that primary human HPC can,
in fact, undergo leukemic transformation in response to theMLL-
AF9 chimeric oncogene in a manner that faithfully recapitulates
many features of the clinical disease. LikeMLL-AF9 patient sam-
ples, normal human CB cells retrovirally transduced with MA9
display essentially unlimited replicative potential, have myelo-
monocytic or pro-B cell features, and are leukemogenic in
mice. Moreover, the transcriptome of these experimentally cre-
Figure 6. Gene Expression Profile of MLL-
AF9-Expressing Cells Resembles Human
AML
(A) The plot depicts the principal component anal-
ysis of data for the 100 most differentially ex-
pressed genes in the CBF versus MLL leukemia
samples from two published studies. Cell culture
samples group closely with the respective pa-
tient samples from the two independent studies.
Additionally, the plot suggests a closer relation-
ship of cell culture samples to the pediatric AML
data set (Ross).
(B) Hierarchical clustering of differentially ex-
pressed genes. The graph shows the heatmap of
CBF and MLL leukemia patient samples as well
as their respective cell culture samples (rows)
based on the 100 genes (columns) most differen-
tially expressed in CBF versus MLL leukemia
samples.
ated cell lines extensively parallels that
of primary leukemia cells from AML pa-
tients with MLL fusions. This model
should prove useful for screening poten-
tial therapeutic compounds, as demon-
strated by the exquisite sensitivity of the
MA9 cells to inhibition of the Rac signal-
ing pathway.
These data suggest that expression of
MA9 is the primary molecular defect re-
sponsible for the defining characteristics
of this disease. Our results support the
hypothesis, based on clinical observa-
tions, that MLL fusion genes require
fewer independent oncogenic events for
leukemic transformation than other fu-
sion oncoproteins.MLL fusions are asso-
ciated with the shortest latency periods
documented between the appearance
of a karyotypic abnormality and the clini-
cal manifestation of malignancy. MLL rearrangements arise in
utero, are found in the majority of infants with acute leukemia,
and are unique in their ability to produce overt clinical disease
after only a few months (Ford et al., 1993). In the present study,
the primary leukemia in NS-SGM3 mice was extremely rapid,
with a median latency of 7 weeks for direct injection of MLL-
AF9-transduced cells (Figure 2A). It could be argued that the
nonphysiologic levels of human growth factors in the NS-
SGM3 mice are contributing to the leukemogenesis, which is
possible. However, even in the NS and NS-B2M mice, the rapid-
ity of the AML (median latency of 9 weeks; Figure S2C) and the
multiclonal as well as multilineage nature of the disease argues
that the need for additional cooperating events is rapidly met
under these experimental conditions. Combined with the clinical
observations, our data suggest that, although MLL fusions alone
are not sufficient to drive leukemogenesis, they somehow facili-
tate the rapid acquisition of the additional genetic or epigenetic
events that are required.490 Cancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc.
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that the initiation of a self-renewal program by MA9, as demon-
strated by others (Krivtsov et al., 2006), includes this critical
enzyme. Although the hTERT promoter itself may not be a direct
target of MLL fusion proteins, sustained hTERT activity is likely
to be one of the essential components of transformation and is
a valid therapeutic target for MLL leukemias. Numerous failed at-
tempts have been made to transform the human HSPC using
leukemia-associated oncogenes, and in all cases where telome-
rase activity has been analyzed it was shown to be low to absent
(Mulloy et al., 2003; Warner et al., 2005; Wunderlich et al., 2006).
It is likely not coincidental that the oncogene that successfully
transforms the human HSPC also results in sustained activity
of telomerase. Our demonstration that FLT3L is also critical for
Figure 7. Suppression of MA9 Cell Growth
by a Rac-Specific Inhibitor, NSC23766, and
by Rac1 Knockdown
The transduced, long-term-cultured MA9 and AE
cord blood cells and 2 week cultured cord blood
cells were plated in the presence of various con-
centrations of NSC23766 as indicated. (A) Forty-
eight-hour cell growth was measured by a MTT as-
say using absorbance at 570 nm. (B) Forty-eight-
hour cell-cycle arrest was analyzed by propidium
iodine staining and flow cytometry. (C) Forty-
eight-hour apoptosis response was analyzed by
Annexin V staining and flow cytometry. In (A)–(C),
data represent the mean ± SD. At least three ex-
periments were performed using three different
MA9 cell cultures. *p < 0.001, or **p < 0.05,
NSC23766-treated versus nontreated cells. (D)
Bcl-2 and Bcl-xL protein levels after 24 hr of
drug treatment. Asterisks indicate potentially
ubiquitinated protein, and arrowheads designate
possible degradation products. (E) Lentiviral
knockdown of Rac1 in MA9 and AE cells results
in specific induction of apoptosis in the MA9 cells
as shown by Annexin V/7-AAD staining. Two inde-
pendent Rac-targeting shRNA were used. (F) The
mean ± SD of three to five experiments is shown.
*p < 0.05, **p < 0.001.(G) Western blot for Rac1
protein expression demonstrates the loss of ex-
pression in the YFP-sorted cells that received the
shRac constructs.
self-renewal of the MLL LSC is in keeping
with previous experimental and clinical
findings associating increased FLT3 ex-
pression with MLL leukemia (Armstrong
et al., 2003, 2004; Ozeki et al., 2004;
Stam et al., 2005; Stubbs and Armstrong,
2007; Stubbs et al., 2008). This could also
explain our ability to expand the MLL LSC
in vitro indefinitely, while Barabe et al.
were unable to maintain the leukemic
clone beyond 3 months; in their study,
only the cytokines IL-3 and SCF were
used (Barabe et al., 2007).
The clonal relatedness of phenotypi-
cally unique leukemias implies that a leu-
kemia stem cell expressing MA9 can be
multipotent, and our data demonstrate that this ability resides
in both the CD19+CD33 and CD19CD33+ cells. Although
this has been previously described for murine cells expressing
the MLL-GAS7 fusion, it is not found with the more common
MLL-ENL or MLL-AF9 fusions, which almost exclusively result
in AML in the mouse (So et al., 2003a). Whether this is a
mouse/human difference remains to be determined but seems
likely based on current data. Zeisig et al. showed that, although
MLL-ENL transduced murine BM cells appeared myeloid by
morphology, even under lymphoid growth conditions, their
gene expression profile and the presence of a rearranged immu-
noglobulin locus strongly favored a B lymphoid ancestry and
a continued transcription factor promiscuity that belied a simple
AML classification (Zeisig et al., 2003). Thus it may be that murineCancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc. 491
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readout of the lymphoid disease associated with the common
MLL fusions.
In our model, lineage-restricted MLL LSC are immortal and
leukemogenic, although they are not multipotent. This raises
questions as to the true nature of the LSC in the human disease.
Since MA9 expression is predominantly associated with AML in
humans, our data could imply that the target cell in MA9-associ-
ated disease is frequently a committed myeloid progenitor cell.
Alternatively, it is possible that the microenvironment in the hu-
man, or the fusion protein itself, strongly promotes a myeloid
phenotype from a primitive LSC. It has been proposed that the
fusion partner is instructive as to lineage (Barabe et al., 2007;
Chen et al., 2006). However, given the ease with which the
MA9 oncogene immortalizes human B cells and induces B-
ALL, it seems unlikely that the fusion partner is the major deter-
minant for lineage choice. Although Barabe et al. have argued
that the xenograft model may skew the outcome toward over-
representation of B-lineage cells, our data would instead support
the hypothesis that environmental cues supplied by the microen-
vironment are playing a primary role in lineage determination. We
clearly show that a B cell outcome is readily attained in vitro upon
expression of the MA9 fusion protein, a finding that is indepen-
dent of xenograft effects (Figure 1F). In addition, the rapid occur-
rence of AML in NS-SGM3 would support the primary effect of
microenvironment on lineage decision. It is obvious, given the
definitive associations between fusion partner identity and line-
age outcome, that additional factors are involved, including
contributions from the individual fusion partner as well as possi-
ble differences in the cell that is targeted by the translocation. It
will be interesting to analyze the effects of MLL-ENL (and MLL-
AF4) in NS-SGM3 mice, and to determine whether MA9 is
able to transform a committed myeloid or lymphoid human pro-
genitor cell.
The progenitor cell in the MA9 lymphoid cultures is reminiscent
of the bipotential B-macrophage progenitor that has been de-
scribed in murine fetal liver and adult mouse bone marrow (Cu-
mano et al., 1992; Montecino-Rodriguez et al., 2001). It is possi-
ble that the transcriptional program initiated and sustained by
MA9 expression favors this particular progenitor cell. Our ability
to manipulate these cells using specific growth factors, to induce
either B lineage or myeloid/macrophage progeny, implies that
the interplay between transcription factors downstream of these
cytokine receptors are finalizing the fate of the cell and promot-
ing lineage restriction. This effect must be instructive rather than
simply promoting survival and outgrowth of a limited number of
previously committed myeloid cells, based on our ability to pro-
mote myeloid differentiation from a pure CD19+CD33 popula-
tion (Figure 5). It is clear from a number of recent studies that the
plasticity of the hematopoietic system is significantly greater
than the simplified hierarchies that have been used in the past,
and our data would support the conclusions of these studies
(Iwasaki et al., 2003, 2006; Xie et al., 2004). This human-based
cell culture system should allow us to address which factors
are involved in these decisions.
The significant and specific effect of NSC23766 on MA9 cells
could reveal a potential vulnerability of MLL fusion leukemias.
Due to its relatively low affinity and pharmacodynamic proper-
ties, this particular version of the compound may not be clinically492 Cancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc.applicable. However, the results highlight the usefulness of this
human-based system for identifying additional pathways for
therapeutic targeting. When better Rac inhibitors become avail-
able, they may prove particularly useful in leukemia patients with
11q23 disease. Rac knockdown was highly effective in recapitu-
lating the drug response, resulting in rapid induction of apoptosis
that was specific for the MA9 cells and did not occur in the
AML1-ETO-expressing cells. How the AML1-ETO cells are by-
passing this particular pathway, and the specific signals up-
stream of Rac that are inducing this addiction are interesting
questions that can be addressed using this model system.
It is intriguing to speculate thatMLL rearrangements, by simul-
taneously creating a state of haploinsufficiency and inducing
expression of a chimeric form ofMLL, may result in global epige-
netic changes. These changes could provide opportunities for
individual clones to rapidly achieve a selective advantage based
on aberrant gene expression patterns. This could lead, for exam-
ple, to failure to downregulate hTERT, allowing cells to continue
replication beyond the normal limits imposed by telomere short-
ening. The striking overlap between the transcriptome of MA9-
transduced human CB cells and their clinical counterparts sug-
gests that whatever effectsMLL-AF9 is having on its direct target
genes and their downstream effectors can be modeled in the
laboratory using primary human CD34+ cells. This system prom-
ises to yield valuable insights into the early events inMLL fusion-
driven leukemogenesis, some of which may be directly trans-
lated into clinical interventions.
EXPERIMENTAL PROCEDURES
CD34+ CB Cells
Human umbilical CB was obtained by the Translational Trials Support Labora-
tory at CCHMC under a protocol approved by the CCHMC Institutional Review
Board. No identifying information related to the infant or mother was obtained
with these collections. CD34+ cells were enriched to >90% purity by immuno-
magnetic bead selection and cryopreserved. Cells were cultured in IMDM 20%
bovine calf serum (or serum-free for some experiments) and supplemented
with SCF, IL-3, IL-6, Flt-3L, and TPO. Viable cell counts in MA9 and control cul-
tures were assessed one to two times per week, and cultures were split into
fresh media as needed to maintain a cell density of between 5 3 105 and
2 3 106 cells/ml.
Flow Cytometry
Cells were analyzed on a FACSCalibur or FACSCanto flow cytometer (BD). Ap-
proximately 2 3 105 cells were stained with fluorochrome-conjugated anti-
bodies for 30 min at 4C and were washed with PBS/2% FBS prior to analysis.
Animal tissues were processed according to standard procedures. Following
red cell lysis, cells were incubated with an antibody to block nonspecific bind-
ing (anti-mouse CD16/CD32 Fcg receptor; BD). 7AAD was used to gate viable
cells. Antibodies (all BD unless noted) used were the phycoerythrin (PE) con-
jugates anti-CD4, -CD8, -CD11b, -CD13, -CD14, -CD16, -CD19, -CD20,
-CD33, -CD34, -CD38, -CD41, -CD56 (Caltag), -CD117, -CD123, -CD135,
and -HLA-DR (Caltag) and the allophycoerythrin (APC) conjugates anti-
CD15, -CD19, -CD33, -CD34, -CD36, -CD110, -CD117, -CD135, and
-CD133 (Miltenyi Biotech). Appropriate IgG isotype control antibodies (BD)
were used. Cell-cycle analysis (BrdU-APC kit, BD) and apoptosis analysis
(Annexin V-PE kit, BD) were performed according to the manufacturer’s rec-
ommendations. All flow cytometry data were analyzed with FloJo software
(TreeStar).
Retroviral Vectors and Viral Transduction
The MIEG3 vector and the RD114 pseudotyping vector were obtained from Dr.
David Williams. SFb91 (REW) vector was from C. Baum. MSCV-MLL-AF9
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encoding MLL-AF9 was a kind gift from J. Kersey and J. Hess. A 4.7 kbp frag-
ment containing MLL-AF9 was cloned, in frame, downstream of the foot and
mouth disease virus (FMDV) 2A peptide (a kind gift from C. Baum). The 2A-
MLL-AF9 fragment was cloned downstream of an EGFP cassette in SFb91.
MIEG3, MA9, and AE vector constructs were transfected transiently into the
Phoenix packaging cell line with either the RD114 or amphotropic env con-
struct and the gag-pol expression plasmid. Supernatant (40 ml) was concen-
trated 83 for RD114-pseudotyped virus and snap frozen. For transduction,
CD34+ cells were cultured in the presence of retroviral supernatant supple-
mented with SCF, IL-3, IL-6 Flt-3L, and TPO on retronectin-coated plates for
2 days.
shRNA Constructs and Lentiviral Transduction
Lentiviral shRac1 vector MISSION pLKO.1-shRac1-puro constructs were
obtained from Sigma. The insert encoding YFP was excised from the
pLKO.1-scrambled-YFP vector (gift of Dr. Lee Grimes) with Kpn1/BamH1
and subcloned into the Kpn1/BamH1 site of pLKO.1-shRac1 vector #677
(CCGGGCTAAGGAGATTGGTGCTGTACTCGAGTACAGCACCAATCTCCTTA
GCTTTTT) and #340 (CCGGCCCTACTGTCTTTGACAATTACTCGAGTAATT
GTCAAAGACAGTAGGGTTTTT), replacing puromycin. 293T cells cultured in
DMEM with 10% FBS were cotransfected with the pMD.2 VSV-G envelope
plasmid, the pCDLN helper plasmid, and the lentiviral vectors by calcium
phosphate transfection. Virus was collected and filtered through a 0.45 mm
filter, concentrated, and purified with 20% sucrose. For transduction, AE and
MA9 cells were cultured in the presence of lentiviral supernatant supple-
mented with SCF, IL-3, IL-6, Flt-3L (and for AE cells, TPO was also included)
on retronectin-coated plates overnight. Two to three days after transduction,
cells were sorted for YFP expression on a FACSVantage (Becton Dickinson,
San Jose, CA). Two, five, and seven days after sorting, cells were assessed
for apoptosis using the annexin V-PE kit (Becton Dickinson) according to the
manufacturer’s directions.
Telomerase Assays
Cellular extracts were prepared from control and MA9 cells in 13 CHAPS lysis
buffer and cleared by centrifugation for 20 min at 4C. Telomerase activity was
assayed with the kit from Intergen.
Mouse Studies
Cultured MA9 cells were injected by tail vein or intrafemoral injection into sub-
lethally irradiated (300–350 rad) 6- to 8-week-old NOD/SCID, NOD/SCID-
B2M, or NOD/SCID-SGM3 mice (Feuring-Buske et al., 2003). Mouse experi-
ments were performed in accordance with relevant institutional and national
regulations and approved by the Institutional Animal Care and Use Committee
of CCHMC. Mice were kept on chow supplemented with doxycycline for 1
week before and after injections. Mice were sacrificed when they showed
signs of illness. Organs were homogenized and processed for flow cytometry
after fixing a piece in 10% formalin for histopathologic analysis. Cells were
grown in vitro for karyotype analysis. The four long bones of the hind legs
were flushed to extract the bone marrow, and the majority of cells were frozen
for injection into secondary recipients.
Histopathology and Karyotype Studies
Organ samples were preserved in 10% formalin before being embedded in
paraffin, sectioned, and stained with hematoxylin and eosin by the Pathology
department at CCHMC. Stained sections were visualized using a Nikon Opti-
phot-2 microscope and photographed with a Spot RT color camera (Diagnos-
tic Instruments Inc). Cytospins were made using the Cytospin-4 centrifuge
(Thermo Shandon). Cytospins were stained by Wright-Giemsa (Fisher Scien-
tific). Metaphase cells were prepared by standard cytogenetics methods. Kar-
yotypes were described according to the International System for Human
Cytogenetic Nomenclature.
NSC Treatment Studies, Apoptosis, and Cell-Cycle Analysis
NSC23766 was resuspended in PBS to obtain a 100 mM stock solution. In vitro
cultures were seeded at 106 cells/ml and incubated with the indicated doses.
Twenty-four to forty-eight hours later, cells were analyzed for Annexin V stain-
ing by flow cytometry according to the manufacturer’s recommendations (An-nexin V-PE kit, BD). Cell cycle was assessed by BrdU incorporation for 1 hr fol-
lowed by flow cytometry using the Anti-BrdU-PE kit (BD). Whole-cell lysates
were made with glycerol lysis buffer (10% Glycerol, 20 mM Tris-HCl, 135mM
NaCl, 1 mM EGTA, 1.5 mM MgCl2, 1% Triton X-100) supplemented with Com-
plete Protease Inhibitor Cocktail (Roche). Protein concentrations were deter-
mined using the BCA protein kit (Pierce), and 25 mg of protein was loaded
onto 14% Tris-Glycine gels (Invitrogen). Western blot analysis was preformed
with primary antibodies against Bcl-2 (BD transduction labs), Bcl-xL (Cell Sig-
naling), and B-actin (Sigma) followed by incubation with HRP-conjugated sec-
ondary antibodies (Cell Signaling) and detection of signal with the SuperSignal
ECL kit (Pierce) with BioMax L1 film (Kodak).
GTPase Pull-Down Assay
To detect active GTP-bound Rac1 and Cdc42, we performed pull-down as-
says using Glutathione S-transferase (GST)-PAK1-PBD beads. Cells (15 3
106) were plated with or without NSC23766 (40 mm) for 24 hr and lysed in
600 ml lysis/binding/washing buffer. One-tenth of the lysate was used for total
Rac1 and total Cdc42 determination by western blot with the remaining lysate
incubated with GST-Pak1-PBD at 4C for 1 hr. After incubation, the mixture
was centrifuged at 8000 3 g. The resins were washed three times with wash
buffer and eluted by adding 50 ml of 13 SDS sample buffer and boiling at
100C for 5 min. The sample volume (20 ml) was analyzed by SDS-PAGE
(15% polyacrylamide gel) and transferred to nitrocellulose membrane. Active
Rac1 and Cdc42 were detected by western blotting. Detection was performed
using SuperSignal West Pico Chemiluminescent Substrate followed by expo-
sure to X-ray film. The band intensity was quantified, and levels of Rac1-GTP
and Cdc42-GTP were normalized to the amount of total protein.
Real-Time RT-PCR
RNA was isolated with the RNAeasy kit (QIAGEN). RNA was reversed tran-
scribed using MuLV RT and random hexamers (Applied Biosystems). The
cDNA was then subject to QPCR using SYBR Green technology (Applied Bio-
systems). Reactions were run on a 7700 system, and data were analyzed using
SDS version 1.9 (Applied Biosystems). Expression levels of hTERT, HOXA9,
FLT3, and SPARC were calculated by the standard curve method relative to
THP-1 and K562 cells. Only samples with the appropriate dissociation curves
were considered for analysis. Results were normalized to c-abl expression.
Q-PCR primers are available upon request.
Southern Blot Analysis
Genomic DNA was prepared using the QIAamp DNA Blood Mini kit (QIAGEN).
DNA (10 mg) was cut with either HinDIII (REW-MA9 construct) or EcoR1
(MSCV-MA9-puro construct) overnight, run on a 0.7% agarose gel for 16–20 hr
at 20V, and transferred to a positively charged nylon membrane (GE Mag-
nacharge) by upward capillary transfer for 16–20 hr in 203 SSC. The DNA
was fixed to the membrane in a UV Stratalinker 1800 (Stratagene). The mem-
brane was prehybridized for 45 min in Hybrisol (Chemicon). The probe (NEBlot
kit, New England Biolabs) was added to 10 ml fresh Hybrisol and incubated
overnight. The membrane was then washed and exposed to Kodak BioMAX
MS film (Fisher).
Microarray Data Analysis
We pooled Affymetrix GeneChip microarray (U133A) data from MLL and CBF
patients from two published leukemia studies (Ross et al., 2004; Valk et al.,
2004). Within these data sets we identified a total of 40 MLL and 76 CBF leu-
kemia samples (training data). Training data were combined with expression
data for the probe sets of the U133A array from our leukemia culture model
microarray (U133+2) data (test data). For further processing of this data matrix,
we utilized the statistical programming language R (http://www.R-project.org/)
with the Bioconductor package (http://www.bioconductor.org/). The data
were preprocessed using the MAS5 function (Affy package). A three-para-
meter linear model was fitted to the training data. Using the empirical Bayes
function (limma package) we identified probe sets differentially expressed be-
tween CBF and MLL patient samples. Probe sets were declared significantly
differentially expressed if their Bonferroni-adjusted p value < 0.01. We identi-
fied the 100 most significantly differentially expressed probe sets representing
distinct genes, excluding those probe sets specific for fusion gene partners. To
visualize the relation of patient leukemia samples and leukemia model cultureCancer Cell 13, 483–495, June 2008 ª2008 Elsevier Inc. 493
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(Matlab, Math Works Inc., version 7.1). Hierarchical clustering (squared Euclid-
ean distance measure) of samples was performed using R/Bioconductor. Fur-
thermore, k-means clustering with a correlation-based metric was conducted
using Matlab.
Sample Classification using SVMs
To investigate whether (a subsetof) the100differentially expressed genes are able
to discriminate MLL and CBF cultures, we used classifiers generated by a linear
SVM. We trained the SVM (Matlab) with expression data from the ten most differ-
entially expressed genes of the training data set. Our culture data (test data) were
then classified according to the classification rule based on the leukemia data
(training data). Also, we performed 10-fold crossvalidation by repeatedly building
classifiers based on 90% of randomly selected samples from the combined test
and training data to classify the remaining 10% of samples.
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